# DICE Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dice-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.dicetherapeutics.com/
- Total disclosed funding: $155M
- Latest round: Series C (Aug 24, 2021)
- Investors on record: 15

## About

Based in California, US, and founded in 2013 by founder and CEO Kevin Judice and Phil Patten, DICE Therapeutics, Inc. operates as a developer of a transformative platform to discover novel small molecules. As of August 2021, the company had raised a total of USD 187.4 million in financing. The company raised USD 204 million in an initial public offering (IPO) on the Nasdaq under the ticker code DICE in September 2021.

DICE Therapeutics, Inc. operates as a biotechnology company that develops small molecule compounds for targeted oral medicines through protein-protein interaction (PPI) therapeutics to treat patients with serious medical conditions.

The funds collected from the IPO in September 2021, will be used to promote the development of oral medicines that might compete with biological treatments.

## Funding rounds

- Series C, Aug 24, 2021, $60M — OUP (Osage University Partners), New Leaf Venture Partners, Driehaus Capital Management, Asymmetry Capital Management, RA Capital Management, Eventide Asset Management, Sands Capital Alternatives, Janus Henderson Investors, Northpond Ventures, Soleus Capital, Logos Capital, Deep Track Capital
- Series C, Jan 8, 2021, $54M — Alexandria Venture Investments, OUP (Osage University Partners), New Leaf Venture Partners, Altitude Life Science Ventures, Driehaus Capital Management, Asymmetry Capital Management, RA Capital Management, Eventide Asset Management, Sands Capital Alternatives, Agent Capital, Northpond Ventures, Soleus Capital
- Series C, Dec 18, 2020, $0.1M — Northpond Ventures
- Series B, Jul 11, 2018, $41M — Agent Capital, Northpond Ventures

## Investors

- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B, Series C
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series C
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series C
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series C
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series C
- Driehaus Capital Management (https://capitalatlas.ai/funds/driehaus-capital-management) — Series C
- Asymmetry Capital Management — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series C
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series C
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series C
- Janus Henderson Investors — Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series C
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series C